Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetyl-L-carnitine in ALS
NCT06126315Phase 3Recruiting
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Mar 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of acetyl-l-carnitine in amyotrophic lateral sclerosis (ALS), sponsored by Mario Negri Institute for Pharmacological Research. Started Mar 2025; status: recruiting.
02
Drugs
acetyl-l-carnitine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06126315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126315.